STAT+: Pharmalittle: We’re reading about upbeat results for a Duchenne drug, Takeda layoffs, and much more

Rise and shine, everyone, another busy day is on the way. And it is getting off to a pleasant start here on the Pharmalot campus, where clear blue skies and comfy breezes are greeting us. Who could ask for anything more? Actually, we could —&#x A0;it is time to reheat the kettle for another cuppa stimulation. Our choice today is apple hibiscus. And here is a helpful tip — a teaspoon of honey enhances the flavors splendidly. Of course, you are invited to join us. For the full experience, we are now hawking replicas — take a look. Meanwhile, here are a few tidbits to help you along. As always, do keep in touch. We appreciate feedback, criticism, and tips. … Biogen reported mixed results from a mid-stage clinical trial investigating a treatment for Alzheimer’s disease that targets the protein tau that, like the better-known amyloid, is toxic to neurons and is believed to play a role in the cognitive decline of patients with the disease, STAT says. In the Phase 2 study, the Biogen drug, called diranersen, reduced levels of tau in the spinal fluid and brains of patients with early-stage Alzheimer’s. Those tau reductions also correlated to a slowing of cognitive decline. Reducing tau in the brain has been accomplished by other drugmakers with antibody treatments, but tying those reductions to a meaningful slowing of cognitive decline has been challenging. Multiple efforts to date have proven unsuccessful. With diranersen, Biogen is trying a different approach. The drawback is the drug must be administered via a spinal injection. Takeda Pharmaceutical plans to cut about 4,500 jobs in fiscal year 2026, as it ‌pushes ahead with a restructuring to centralize corporate functions ‌and reduce costs, Reuters notes. The company expects annual savings of more than $1.27 billion by fiscal 2028, but did not provide details about the timeline and which ‌roles will be affected. Takeda has been in the midst ⁠